IHS Chemical Week

Regions :: North America :: U.S.

FDA issues warning letter to Boehringer Ingelheim API plant

4:39 AM MDT | May 22, 2013 | Deepti Ramesh

FDA issued a warning letter earlier this month to the active pharmaceutical ingredient (API) and finished pharmaceutical manufacturing facility Boehringer Ingelheim (Ingelheim am Rhein, Germany) at Ingelheim am Rhein for violations of cGMP. An FDA inspection of the facility from 5–12 November 2012 identified significant violations of cGMP for the manufacture of APIs and the cGMP regulations for finished pharmaceuticals, FDA says. The warning letter was published in the FDA website on 21 May. The violations for the manufacture of APIs at the Ingelheim am...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa